Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Cologuard® 2.0

Exact Sciences aims to build on the success of Cologuard® through the development of Cologuard 2.0, a stool DNA test with enhanced performance characteristics without losing the simplicity and convenience of an at-home test. The goals with Cologuard 2.0 are to increase test performance and further improve the patient experience to reinforce Cologuard as the best-in-class non-invasive screening option. Samples collected from the BLUE-C clinical trial will be used to establish the performance characteristics of Cologuard 2.0 and support a submission for FDA approval.